Karlsson Niklas, Atkinson Mark J, Müllerová Hana, Alacqua Marianna, Keen Christina, Hughes Rod, Janson Christer, Make Barry, Price David, Reddel Helen K
BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden.
Evidera, Bethesda, MD, USA.
ERJ Open Res. 2021 Feb 1;7(1). doi: 10.1183/23120541.00828-2020. eCollection 2021 Jan.
The Respiratory Symptoms Questionnaire (RSQ) is a novel, four-item patient-reported diagnosis-agnostic tool designed to assess the frequency of respiratory symptoms and their impact on activity, without specifying a particular diagnosis. Our objective was to examine its validity in patients with asthma and/or chronic obstructive pulmonary disease (COPD).
Baseline data were randomly sampled from patients who completed the RSQ in the NOVELTY study (ClinicalTrials.gov: NCT02760329). The total sample (n=1530) comprised three randomly selected samples (n=510 each) from each physician-assigned diagnostic group (asthma, asthma+COPD and COPD). The internal consistency and structural validity of the RSQ were evaluated using exploratory and confirmatory factor analyses; psychometric performance was observed using Classical Test Theory and Item Response Theory analyses.
For the total sample, the mean±sd RSQ score was 5.6±4.3 (range 0-16). Irrespective of diagnosis, the internal consistency of items was uniformly adequate (Cronbach's α=0.76-0.80). All items had high factor loadings and structural characteristics of the measure were invariant across groups. Using the total sample, RSQ items informatively covered the θ score range of -2.0 to 2.8, with discrimination coefficients for individual items being high to very high (1.7-2.6). Strong convergent correlations were observed between the RSQ and the St George's Respiratory Questionnaire (0.77, p<0.001).
The RSQ is a valid, brief, patient-reported tool for assessing respiratory symptoms in patients across the whole spectrum of asthma and/or COPD, rather than using different questionnaires for each diagnosis. It can be used for monitoring respiratory symptoms in clinical practice, clinical trials and real-world studies.
呼吸症状问卷(RSQ)是一种新颖的、包含四个条目的患者报告诊断无关工具,旨在评估呼吸症状的频率及其对活动的影响,而不指定特定诊断。我们的目的是检验其在哮喘和/或慢性阻塞性肺疾病(COPD)患者中的有效性。
基线数据从在新颖性研究(ClinicalTrials.gov:NCT02760329)中完成RSQ的患者中随机抽样。总样本(n = 1530)包括从每个医生指定诊断组(哮喘、哮喘+COPD和COPD)中随机选择的三个样本(每个n = 510)。使用探索性和验证性因素分析评估RSQ的内部一致性和结构效度;使用经典测试理论和项目反应理论分析观察心理测量性能。
对于总样本,RSQ平均得分±标准差为5.6±4.3(范围0 - 16)。无论诊断如何,项目的内部一致性均一致良好(Cronbach's α = 0.76 - 0.80)。所有项目具有高因素负荷,且该测量的结构特征在各组间不变。使用总样本,RSQ项目可有效覆盖-2.0至2.8的θ分数范围,单个项目的区分系数为高到非常高(1.7 - 2.6)。在RSQ与圣乔治呼吸问卷之间观察到强收敛相关性(0.77,p < 0.001)。
RSQ是一种有效的、简短的、患者报告的工具,用于评估整个哮喘和/或COPD范围内患者的呼吸症状,而不是针对每种诊断使用不同问卷。它可用于临床实践、临床试验和真实世界研究中的呼吸症状监测。